| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-04-14 | BI-1206 | preclinical | BioInvent (Sweden) | Cancer - Oncology | |
| 2015-04-14 | BAY 80-6946 - copanlisib | recurrent indolent Non-Hodgkin’s lymphoma (NHL) |
2,3 | Bayer Healthcare (Germany) | Cancer - Oncology - Rare diseases |
| 2015-04-14 | BAY 80-6946 - copanlisib | diffuse large B-cell lymphoma (DLBCL) |
2,3 | Bayer Healthcare (Germany) | Cancer - Oncology |
| 2015-04-14 | Firdapse™ (amifampridine phosphate or 3,4-diaminopyridine (3,4-DAP) phosphate) | Lambert-Eaton Myasthenic Syndrome (LEMS) |
3 | Catalyst Pharmaceutical Partners (USA - FL) | Autoimmune diseases - Neuromuscular diseases - Rare diseases |
| 2015-04-13 | IDO1, TDO and IDO1/TDO Dual Inhibitor programs | preclinical | Iomet Pharma (UK) | Cancer - Oncology | |
| 2015-04-10 | once-daily extended release formulation of lorcaserin | weight management |
1 | Eisai (Japan) Arena Pharmaceuticals (USA - CA) | Metabolic diseases |
| 2015-04-10 | GZ389988 | osteoarthritis | 1 | Genzyme (USA - MA), a Sanofi company (France) | Inflammatory diseases - Rheumatic diseases |
| 2015-04-09 | LUM001/SHP625 (maralixibat) (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride | Alagille syndrome | 2 | Shire (UK-USA) | Hepatic diseases - Liver diseases - Rare diseases |
| 2015-04-09 | masitinib | pancreatic cancer | 3 | AB Science (France) | Cancer - Oncology |
| 2015-04-08 | simeprevir (Olysio®) in combination with sofosbuvir and daclatasvir | patients with hepatitis C genotype 1 and 4 infection and decompensated liver disease | 2 | Medivir (Sweden) Janssen Pharmaceuticals, a J&J company (USA - NJ) | Infectious diseases |
| 2015-04-08 | simeprevir (TMC435) and sofosbuvir | chronic genotype 1 hepatitis C virus (HCV) infection |
3 | Medivir (Sweden) Janssen Pharmaceuticals, a J&J company (USA - NJ) Idenix Pharmaceuticals (USA) | Infectious diseases |
| 2015-04-08 | CAP-1002 | advanced heart failure |
1 | Capricor Therapeutics (USA - CA) | Cardiovascular diseases |
| 2015-04-08 | ADXS-PSA/ADXS31-142 and Keytruda® (pembrolizumab) | metastatic castration-resistant prostate cancer (mCRPC) |
1-2 | Advaxis (USA - NJ) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-04-08 | rexlemestrocel-L (MPC-06-ID) | chronic low back pain due to degenerative disc disease | 3 | Mesoblast (Australia) | CNS diseases - Bone diseases |
| 2015-04-07 | 1404 | prostate cancer | 2 | Progenics Pharmaceuticals (USA - NY) FUJIFILM RI Pharma (Japan) | Cancer - Oncology - Diagnostic |
| 2015-04-06 | OTX-DP (sustained release dexamethasone) | ocular inflammation pain following cataract surgery |
3a | Ocular Therapeutix (USA - MA) | Ophtalmological diseases |
| 2015-04-06 | ALKS 3831 | schizophrenia | 2 | Alkermes (Ireland) | Mental diseases |
| 2015-04-06 | varlilumab, ipilimumab CDX-1401 | unresectable stage III or stage IV melanoma | 1-2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology |
| 2015-04-06 | Glybera® (alipogene tiparvovec) | lipoprotein lipase deficiency (LPLD) |
uniQure (The Netherlands) Chiesi Farmaceutici (Italy) | Genetic diseases - Rare diseases | |
| 2015-04-02 | TV-45070 (formerly XEN402) | postherpetic neuralgia |
2b | Teva Pharmaceutical Industries (Israel) Xenon Pharmaceuticals (Canada) | CNS diseases - Neurological diseases |
